AMGN
Amgen·NASDAQ
--
--(--)
Market Open: --
--
--(--)
Pre-Market: --
Signals Analysis
Bullish signal 4
Bearish signal 1
High Gross Profit Margin
High Cash/net Profit Ratio
Revenue Beats Expectation
FDA Approved
EPS Below Expectations
Key Stats
0.0000DAY`S RANGE0.0000
0.000052 WK RANGE0.0000
0.0000
0.0000
--
--
--
--
--
--
--
--
--
--
--
--
--
--
0.0000
0.0000
0.0000
0.0000
About AMGN
Amgen Inc.
A company that develops therapeutics based on cellular and molecular biology to treat cardiovascular and inflammatory diseases
One Amgen Center Drive, Thousand Oaks, California 91320-1799
Develops,manufactures and markets human therapeutic products used in the areas of neurobiology,hematology,infectious disease and inflamations to fightinfection and stimulate the production of blood cells.
Amgen Inc. was founded in California in 1980 and became a Delaware corporation in 1987. The company discovers, develops, manufactures and delivers innovative medicines to fight some of the world's most intractable diseases. The company focuses on areas of high unmet medical needs and uses its expertise to strive for solutions that can significantly improve people's lives while reducing the social and economic burden of disease. The company helped launch the biotech industry more than 40 years ago and has grown into one of the world's leading independent biotech companies.
Earnings Call
Q1/2025
Estimate EPS4.26
Actual EPS4.9
Estimate Revenue8.04B
Actual Revenue8.15B
Amgen's Q1 2025: Contradictions in Obesity Treatment Strategies and Market Dynamics
May 02,2025 07:32
Earnings Decrypt
Earnings Decrypt
Q2/2025
Estimate EPS5.27
Actual EPS6.02
Estimate Revenue8.91B
Actual Revenue9.18B
Amgen's 2025 Q2 Earnings Call: Unraveling Key Contradictions on MariTide, Bema, and Biosimilars Strategy
Aug 05,2025 09:57
Earnings Decrypt
Earnings Decrypt
Company Financials
EPS
AMGN has released its 2025 Q3 earnings. EPS was reported at 5.64, versus the expected 5.01, beating expectations. The chart below visualizes how AMGN has performed over recent quarters, highlighting trends in earnings surprises.
Revenue & Expenses
AMGN has released its 2025 Q3 earnings report, with revenue of 9.56B, reflecting a YoY change of 12.40%, and net profit of 3.22B, showing a YoY change of 13.64%. The Sankey diagram below clearly presents AMGN's revenue sources and cost distribution.
Forecast
Wall Street Opinions
Price Target
Volume Profile
Trade Flow Insight
Seasonals
Community Forum
Loading...
Related News
No articles available
